151 related articles for article (PubMed ID: 34320493)
41. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
42. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
43. Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT).
Ingley KM; Hughes D; Hubank M; Lindsay D; Plumb A; Cox R; Chesler L; Strauss SJ
Lung Cancer; 2021 Aug; 158():151-155. PubMed ID: 34059352
[TBL] [Abstract][Full Text] [Related]
44. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
45. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Peled N; Gillis R; Kilickap S; Froesch P; Orlov S; Filippova E; Demirci U; Christopoulos P; Cicin I; Basal FB; Yilmaz C; Fedor M; Korkmaz T; Paydas S; Gautschi O; Zirtiloglu A; Eralp Y; Cinkir HY; Sezer A; Erman M; Tural D; Turna H; Mazieres J; Dudnik E; Reguart N; Camidge DR; Ng TL; Şenler FÇ; Beypınar İ; Yazılıtaş D; Demirkazık A; Karaoğlu A; Okutur K; Coşkun HŞ; Şendur MAN; Isikdogan A; Cabuk D; Yumuk PF; Yıldız I; Kaplan MA; Özyılkan Ö; Öztop İ; Olmez OF; Aydin K; Aydıner A; Meydan N; Grinberg RD; Roisman LC
Lung Cancer; 2020 Oct; 148():48-54. PubMed ID: 32799090
[TBL] [Abstract][Full Text] [Related]
46. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
47. Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.
Dong L; Xia J; Zhang J; Zhang Y; Zhu N; Zhang P; Zhang Y; Zhang X; Li S
BMC Pulm Med; 2018 Jan; 18(1):13. PubMed ID: 29361925
[TBL] [Abstract][Full Text] [Related]
48. Lorlatinib in ROS1-positive NSCLC.
Killock D
Nat Rev Clin Oncol; 2020 Jan; 17(1):7. PubMed ID: 31705129
[No Abstract] [Full Text] [Related]
49. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
50. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.
Pavlakis N; Cooper C; John T; Kao S; Klebe S; Lee CK; Leong T; Millward M; O'Byrne K; Russell PA; Solomon B; Cooper WA; Fox S
Pathology; 2019 Dec; 51(7):673-680. PubMed ID: 31668406
[TBL] [Abstract][Full Text] [Related]
51. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
[TBL] [Abstract][Full Text] [Related]
52. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
53. Activation of RAS family members confers resistance to ROS1 targeting drugs.
Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
[TBL] [Abstract][Full Text] [Related]
54. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.
Ou SI; Zhu VW
Lung Cancer; 2019 Apr; 130():201-207. PubMed ID: 30885345
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract][Full Text] [Related]
56. Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.
Gibelin C; Avrillon V; De La Fouchardiere A; Mc Leer-Florin A; Lantuejoul S; Fayette J
Lung Cancer; 2016 Dec; 102():42-43. PubMed ID: 27987587
[TBL] [Abstract][Full Text] [Related]
57. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
58. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
59. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
